- Generic name
- Palonosetron
- Strength
- .5 mg
- Dosage form
- Tablet
- Manufactured by
- Renata PLC.
Vomiren Tablet
About Vomiren .5 mg Tablet
Vomiren comes as a tablet with.5 mg of Palonosetron, from Renata PLC. It helps with acute and delayed nausea and vomiting caused by chemotherapy, including on the day of treatment and on later days.
There are 16 brands of Palonosetron listed in Bangladesh.
What is Vomiren .5 mg Tablet?
Vomiren.5 mg tablet is a medicine made by Renata PLC. It is used in situations such as nausea and vomiting after chemotherapy or radiotherapy, and in some cases of uncontrolled or postoperative nausea and vomiting. Its active ingredient is Palonosetron, and it is grouped with anti-emetic medicines, which are used to help manage nausea and vomiting. The doctor decides the dose and course.
Uses of Vomiren
It helps with acute and delayed nausea and vomiting caused by chemotherapy, including on the day of treatment and on later days. It may be used for radiotherapy-related nausea as well. Vomiren is used to help manage nausea and vomiting. Your doctor will decide if it is right for your situation.
How to use Vomiren
Store it in a cool, dry place away from light. Vomiren is taken by mouth. Swallow the tablet with water. If you miss a dose, ask your doctor or pharmacist what to do. The doctor decides the dose, when to take it and how long the course should last.
Side effects of Vomiren
The most common side effects reported with Palonosetron are headache and constipation. Not everyone who takes it will have these effects. Ask the doctor about any other possible effects. Tell your doctor if these bother you or do not settle. Tell your doctor if any side effect bothers you or does not go away.
Safety and precautions
People with other health conditions should check with the doctor first. If you are pregnant, think you may be pregnant, or are breastfeeding, ask your doctor before taking it, because it is not known whether it passes into breast milk. Do not take Vomiren if you have had an allergic reaction to Palonosetron or to any of the ingredients in the tablet. The doctor will decide if it is suitable for you.
Frequently asked questions
Why is Vomiren prescribed?
It helps with acute and delayed nausea and vomiting caused by chemotherapy, including on the day of treatment and on later days. It may be used for radiotherapy-related nausea as well.
How do I use Vomiren correctly?
Store it in a cool, dry place away from light. Vomiren is taken by mouth.
Can Vomiren cause side effects?
The most common side effects reported with Palonosetron are headache and constipation. Not everyone who takes it will have these effects.
Who should be careful with Vomiren?
People with other health conditions should check with the doctor first. If you are pregnant, think you may be pregnant, or are breastfeeding, ask your doctor before taking it, because it is not known whether it passes into breast milk.
Indications
- Acute and delayed nausea and vomiting
- Uncontrolled nausea and vomiting
- Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
- Delayed CINV resulting in on days later with certain types of chemotherapy ... Read more
- Acute and delayed nausea and vomiting
- Uncontrolled nausea and vomiting
- Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
- Delayed CINV resulting in on days later with certain types of chemotherapy
- Radiotherapy-induced nausea and vomiting (RINV)
- Post-operative & Post-discharge nausea and vomiting (PONV & PDNV).
Pharmacology
Pharmacokinetics: Palonosetron exhibits linear dose-proportional pharmacokinetics over the doserange 1-90 pg/kg in healthy subjects and in patients with cancer. In cancer patients receiving single intravenous doses of Palonosetron in this dose range, the mean maximum plasma concentration (Cmax) ranges from 0.89 to 336 ng/ml and the area under the plasma concentration-time curve from zero to infinity (AUCo-co) ranges from 13.8 to 957 ng.h/ml. Palonosetron has a volume of distribution of approximately 6.9-7.9 L/kg, with approximately 62% bound to plasma proteins. Approximately 50% of Palonosetron is metabolized into two inactive metabolites that exhibit <1% of the 5-HT3 receptor antagonist activity. Approximately 40% of the drug is metabolised via kidney, 50% by liver CYP2D6 (mainly), CYP3A4 and CYP1A2 isoenzymes. About 50% of the drug goes under metabolism. After a single intravenous dose, approximately 40% is excreted as unchanged drug in the urine after 144 hours. Total body clearance of Palonosetron is 160±35 ml/h/kg, and renal clearance is 66.5±18.2 ml/h/kg in healthy subjects. Palonosetron exhibits a longer half-life (40 hours) and has a greater 5-HT3 receptor binding affinity.
Dosage & Administration
Chemotherapy-induced nausea and vomiting: Adult tablet dosage: 0.5 mg administered approximately 1 hour prior to the start of chemotherapy. Adult IV dosage: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before the start of chemotherapy.
Radiotherapy-induced nausea and vomiting: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before each week of radiation fraction.
Post-operative nausea and vomiting: A single IV dose of 0.075 mg should be administered over 10 seconds immediately before induction of anesthesia.
Children dosage: (1 month to 17 years): A single IV dose at 20 mcg/kg body weight. Which maximum dose is 1.5 mg.
Interaction
Contraindications
Side Effects
Pregnancy & Lactation
Overdose Effects
Storage Conditions
Alternative brands of Palonosetron
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.